A single, randomized, double-blind, controlled Phase 3 pivotal trial of Rezafungin or the treatment of candidemia and invasive candidiasis

Trial Profile

A single, randomized, double-blind, controlled Phase 3 pivotal trial of Rezafungin or the treatment of candidemia and invasive candidiasis

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Rezafungin (Primary)
  • Indications Candidaemia; Candidiasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 08 Nov 2017 According to a Cidara Therapeutics media release, this and another Phase III trial (see profile 290391) could suffice for approval of rezafungin for both prophylaxis and treatment of invasive fungal infections.
    • 08 Nov 2017 According to a Cidara Therapeutics media release, the company plans to initiate this trial in mid-2018, with topline data expected in mid-2020, subject to feedback from European regulators.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top